SURPASS-IPF: A Phase 3 Study Comparing Deupirfenidone to Pirfenidone, Uses Quantitative HRCT...American College of Chest Physicians (CHEST) Annual Meeting. 2026. Craster A, et al. [Poster]
Previous
Previous
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
Next
Next